Enovis Corporation is a medical technology company that develops clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive. The Prevention and Recovery segment provides orthopedic bracing, therapy devices, and physical therapy products used by healthcare professionals to treat musculoskeletal conditions. The Reconstructive segment develops and distributes surgical solutions for joint replacement, limb reconstruction, and foot and ankle procedures. The company was formerly known as Colfax Corporation, was founded in 1995, and is headquartered in Wilmington, Delaware.
Globus Medical Q2 Revenue Rises 5.9% to $789.6 Million, Beats Estimates
Globus Medical reported second-quarter revenues of $789.6 million, up 5.9% year on year and 0.9% above analysts' expectations, as the medical devices and supplies specialty industry posted a strong quarter overall. The company also beat analysts' full-year EPS guidance estimates and their quarterly EPS estimates, with President and Chief Executive Officer Keith Pfeil citing 6% overall revenue growth, or 9% excluding Nevro, driven by share gains in US Spine, up 7%, and International Spine, up 14% as-reported and 12% on a constant currency basis. Despite the beat, Globus Medical shares are down 8.8% since reporting and trade at $73.94. Across the seven specialty medical device stocks tracked, group revenues beat consensus by 2.1%, with Inspire Medical Systems posting the highest full-year guidance raise of the group and STAAR Surgical delivering the biggest analyst estimate beat and fastest revenue growth, while Enovis turned in the weakest performance against estimates and the weakest guidance update. Inspire Medical Systems shares are up 32.3% since reporting at $69.08, Haemonetics is up 27.8% at $106.86, STAAR Surgical is down 21.8% at $19.87, and Enovis is down 39.6% at $18.24.
GMED · Capital · Positive Globus Medical beat Q2 revenue and EPS estimates with 5.9% revenue growth and raised full-year EPS guidance.
ENOV · Capital · Negative Enovis turned in the weakest performance against estimates and the weakest guidance update among the tracked medical device stocks.
INSP · Capital · Positive Inspire Medical Systems posted the highest full-year guidance raise of the tracked medical device group.
STAA · Capital · Neutral STAAR Surgical delivered the biggest analyst estimate beat and fastest revenue growth, yet its shares are down 21.8% since reporting.
HAE · Capital · Positive Haemonetics shares are up 27.8% since reporting, cited among the strong specialty medical device group results.
Enovis Chief Administrative Officer Oliver Engert Buys 7,598 Shares
Oliver Engert, Chief Administrative Officer of Enovis Corporation, purchased 7,598 shares of common stock in transactions on Sept. 2, 2026, and Sept. 3, 2026, according to a recent SEC Form 4 filing. The purchase was executed at a weighted average price of $19.74 per share, for a total transaction value of roughly $150,000, with the shares acquired in multiple transactions at price ranges of $19.33 to $19.75 and $20.145 to $20.50. The addition brings Engert's total direct holding to 61,238 shares, a stake of 0.11% in the $1.1 billion medical technology enterprise, worth about $1.19 million based on the Sept. 3, 2026 market close of $19.40. Enovis reported trailing twelve-month revenue of $2.3 billion and a net loss of $1.1 billion, while net debt stands at $1.36 billion. The stock closed at $18.56 on Sept. 4, 2026.
Enovis to Acquire eCential Robotics for €155 Million
Enovis has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, for an enterprise value of €155 million, with up to €35 million in milestone payments. The deal, expected to close by the end of 2026, will be funded with cash and revolving-credit capacity, and it expands Enovis' ASTRA ecosystem into robotics. The company plans to launch a next-generation robotic platform for total knee procedures within two years, followed by a shoulder application, with initial commercial contributions expected in 2028. Enovis expects the acquisition to temporarily dilute adjusted EBITDA margins by roughly 100 basis points in 2027, while leverage rises by about half a turn, but it still targets at least $100 million in free cash flow next year.
Robotics & Physical AI › Surgical & Medical Robotics Competition
ENOV · Capital · Positive Enovis is acquiring eCential Robotics for €155M, expanding its ASTRA ecosystem into robotics, though it expects ~100bp EBITDA margin dilution in 2027.
eCential Robotics · Capital · Positive eCential Robotics is being acquired by Enovis for €155M enterprise value plus up to €35M in milestones.
Enovis reaffirms 2026 outlook and targets over 25% free cash flow conversion as Arvis rollout expands
Enovis reaffirmed its 2026 guidance during its second-quarter earnings call, targeting free cash flow conversion of greater than 25%. CEO Damien McDonald reported organic growth of 5%, driven by 6% organic growth in Recon and 3% in P&R, with U.S. Recon led by 8% organic growth in Hips and Knees. CFO Phillip Berry noted second-quarter sales of $583 million, adjusted gross margin of 62%, adjusted EBITDA margin of 17.9%, and adjusted earnings per share of $0.90. The company expects a seasonally softer third quarter followed by sales acceleration in the fourth quarter, supported by the full commercial launch of the Arvis system in the U.S. and continued adoption of the Nebula platform.
Enovis Reaffirms 2026 Revenue Guidance Amid Sales Declines and Weakening Returns on Capital
Enovis has reaffirmed its 2026 revenue guidance of US$2.31 to US$2.37 billion with 4 to 6 percent organic growth, even as it reports annual sales declines and diminishing returns on capital. The company also recorded large impairment charges and ongoing losses, raising concerns that headline growth may not translate into improved profitability. Management’s confidence in the top line contrasts with the weakening efficiency of its capital deployment, which could pressure the investment thesis that Enovis can eventually generate durable, cash-generating growth from its medtech portfolio.
ENOV · Capital · Negative Reaffirmed revenue guidance is overshadowed by sales declines, impairment charges, losses, and weakening returns on capital, indicating poor capital efficiency and profitability.
Intuitive Surgical warning on insurance changes hits medical device stocks
Shares of several medical device companies fell after Intuitive Surgical warned that changes to some insurance plans could slow U.S. procedure growth, sparking fears of a sector-wide slowdown. STAAR Surgical dropped 10.1%, Globus Medical fell 4.4%, Integer Holdings declined 4.1%, and Enovis lost 5.1%. The warning suggests that shifting insurance coverage could dampen the number of medical procedures performed in the United States, creating headwinds for the entire industry reliant on steady procedure volumes.
HCA Healthcare, UnitedHealth, CrowdStrike, RXO, and Enovis make big moves this week
Several stocks made notable moves this week. HCA Healthcare fell 6.7% on Tuesday after releasing preliminary second-quarter results and cutting its full-year 2026 profit guidance. UnitedHealth rose 5.1% on Thursday after reporting second-quarter earnings that surpassed Wall Street expectations, driven by improved profitability. CrowdStrike gained 9.8% on Tuesday after U.S. and international security agencies issued a joint warning about Russian state-sponsored cyber threats targeting critical infrastructure. RXO rose 4.2% on Monday after Stifel raised its price target on the stock to $30 from $22 while maintaining a Buy rating. Enovis rose 3.6% on Monday after announcing the U.S. launch of CT-RevitL, a new veterinary laser therapy system from its Companion Animal Health business.
Innovative Eyewear Soars 63% on Q2 Sales Growth and Retail Expansion
Innovative Eyewear shares surged 63% after the company reported preliminary second-quarter net sales of approximately $0.99 million, a 71% year-over-year increase, and announced new retail partnerships in Canada and the United States. The company received an initial purchase order from a Canadian optical retail group with 345 locations and was awarded a 50-store test with a major U.S. retailer, both expected to begin in the third quarter of 2026. Separately, Seer jumped 35% after its Chair and CEO proposed to acquire all outstanding Class A shares for $2.45 per share in cash plus two contingent value rights, with the board forming a special committee to evaluate the offer. Orthofix and Enovis rallied over 15% each after CMS withdrew reimbursement changes for non-invasive bone growth stimulators, restoring Medicare rates to pre-May 2026 levels. Other notable movers included YD Bio, up 23% on no specific news, and Adlai Nortye, which gained 15% amid progress updates on its cancer therapy pipeline.
Enovis Stock Jumps 15% After CMS Reverses Reimbursement Cuts
Shares of Enovis Corporation jumped 15% after the Centers for Medicare & Medicaid Services reversed previously announced reimbursement cuts for the company's non-invasive bone growth stimulators. The decision marks a significant rebound for the stock, which had declined 12% during a prior session. The positive move was also supported by broader strength in the healthcare sector, which was the top-performing sector in the S&P 500 after a soft June jobs report dampened expectations for interest rate hikes.
Enovis, Insteel Industries, Mueller Water Products, and Proto Labs are highlighted as growth stocks trading under $100 with strong long-term potential. Enovis saw 11% reconstructive sales growth in Q1 2026 and holds a Strong Buy consensus with a $42 average price target, roughly 91% above its current $22. Insteel Industries reported Q2 sales up 7.5% year over year, driven by infrastructure spending and record data center construction permits. Mueller Water Products posted Q2 net sales up 4.6% and benefits from $55 billion in federal water infrastructure funding. Proto Labs is pivoting from prototyping to production-grade manufacturing, with a $1.2 billion market cap and shares at $80.
IIIN · Demand · Positive Insteel Industries reported Q2 sales up 7.5% year over year, driven by infrastructure spending and record data center construction permits.
MWA · Demand · Positive Mueller Water Products posted Q2 net sales up 4.6% and benefits from $55 billion in federal water infrastructure funding.
PRLB · Technology · Positive Proto Labs is pivoting from prototyping to production-grade manufacturing, a strategic technology shift.
United States